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Abstract
Glioblastoma is the most aggressive brain tumor. Gene therapies, such as cytokine-based, 
suicide gene, and oncolytic virus therapies, are different types of treatments from chemo-
therapy such as using temozolomide as a standard treatment. However, overall survival 
was not prolonged in some clinical trials because of the low efficiency of gene transduc-
tion and viral infection. Neural stem cells (NSCs) have tumor trophic migratory capacity 
and can be cellular delivery vehicles of cytokines, suicide genes, and oncolytic virus. NSCs 
can be differentiated from embryonic stem cells. In addition, mesenchymal stem cells can 
be another cellular delivery vehicle. Recently, induced pluripotent stem cells (iPSCs) 
have been established. iPSCs are multipotent; hence, they can efficiently differentiate to 
NSCs and can possibly overcome ethical and practical issues in clinical application. In this 
study, current topics about stem cell therapy for malignant glioma are reviewed.
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1. Introduction
Malignant glioma is the most aggressive brain tumor that accounts for approximately 30% 
of all brain tumors [64]. It is incurable by a conventional standard therapy (maximal tumor 
resection, adjuvant chemotherapy, and irradiation) because brain tumor stem cells have infil-
trative growth and resistance to irradiation and tumoricidal agents [63].
Gene therapies, such as cytokine-based, suicide gene, and oncolytic virus therapies, are differ-
ent types of treatments from chemotherapy, such as using temozolomide, an alkylating agent, 
as a standard treatment for glioblastoma [15, 25, 56]. Some clinical trials have been previously 
conducted; however, prolonged overall survival was not attained. This result was caused by 
the low efficiency of gene transduction and viral infection [56].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Recent studies demonstrated that neural stem cells (NSCs) and mesenchymal stem cells 
(MSCs) have tumor trophic migratory capacity [45, 62]. NSCs and MSCs would be possible 
cellular delivery vehicles of cytokines, suicide genes, or oncolytic virus to tackle gliomas 
[45, 62]. NSCs can be differentiated from certain types of stem cells. Embryonic stem cells 
(ESCs) are established from the inner cell mass in human embryos; however, ESCs have 
ethical issues [73]. MSCs can be easily harvested from the adult bone marrow and the fatty 
tissue. However, further investigation is needed for the affinity of MSCs to the human brain 
[31]. Induced pluripotent stem cells (iPSCs) were established from human adult fibroblasts 
in 2007 [65, 67]. iPSCs have multipotency; hence, they can efficiently differentiate to NSCs. 
iPSCs can possibly overcome ethical and practical issues in clinical application [6, 66].
In this study, current topics about stem cell therapy for malignant glioma are reviewed 
(Figure 1).
2. Gene therapy using viral vector
The characteristics of gene therapies are summarized in Table 1.
2.1. Cytokine-based therapy
Viral vectors such as retrovirus and adenovirus with genes encoding immunostimulatory 
cytokines have been used to treat malignant glioma. This therapy can increase the proliferation 
Figure 1. Viral vectors are tools commonly used to deliver genetic material into tumor cells. However, the efficiency of 
gene transduction by the viral vectors is not high enough to cover the invaded area of malignant glioma. Replication-
competent virus is used for oncolytic virus therapy. Genetically modified oncolytic virus can selectively replicate in 
tumor cells. Viral particles are released and spread to surrounding tumor cells. Some stem cells have tumor trophic 
migratory capacity, which can be possible cellular delivery vehicles of cytokines, suicide genes, or oncolytic virus to 
tackle malignant gliomas. Stem cells have the possibility to cover the large invaded area of malignant glioma.
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of cytotoxic T cells and natural killer cells, enhancing anticancer immune response. Cytokines 
delivered by viral vectors such as interleukin (IL)-2, IL-4, IL-12, and IL-18, granulocyte-mac-
rophage colony-stimulating factor (GM-CSF), interferon-gamma (IFN-γ), costimulating factor 
such as B7–1, and enhancer of immunogenicity such as transforming growth factor-β anti-
sense have been previously investigated. These studies demonstrated the local augmentation 
and ability of the immune response against glioma cells [53, 71, 74].
Recently, tumor suppressor genes are also used for gene therapy to treat malignant gli-
oma. p53, which is known as a common mutagenic target in the development of malignant 
glioma, was evaluated using a replication-deficient adenoviral vector [32]. Phosphatase 
and tensin homolog (PTEN) negatively regulates PI3K. PTEN gene alterations are also 
associated with poor prognosis of malignant glioma. PTEN expression induced by adeno-
viral vector also showed an antitumor response in some experiments [1]. A clinical trial 
using an adenoviral vector with INF-β has also been conducted. However, the efficacy 
of that clinical trial in patients is limited. Therefore, improvement of the vector is cer-
tainly necessary to deliver the genes [14]. On the contrary, some studies suggested the 
advantages of the combination of cytokine-based and standard chemotherapies. In the 
future, combinatorial gene therapy might be effective in the treatment of malignant glioma 
[11, 33, 44, 76].
2.2. Oncolytic virus therapy
Replication-competent viral vectors have been previously used for oncolytic virus therapy. 
The transduction efficiency of replication-competent viral vectors is higher than that of repli-
cation-deficient viral vectors [2]. Genetically modified oncolytic viral vectors can selectively 
Gene therapy Characteristics Types
Cytokine based 
therapy
Cytokine based therapy can increase 
the proliferation of cytotoxic T cells and 
natural killer cells, enhancing anticancer 
immune response.
IL-2, IL-4, IL-12, IL-18, GM-CSF, IFN-γ, B7-1, and 
TGF-β antisense
Oncolytic virus 
therapy
Genetically modified oncolytic viral vectors 
can selectively replicate in tumor cells. 
Viral particles are released and spread to 
surrounding tumor cells.
First generation: HSV1716: γ34.5 gene deleted HSV-1
Second generation: G207: a doubly mutated HSV-1, 
which has deletion of both γ34.5 loci and insertional 
inactivation of UL39
Third generation: G47 delta: a new type of oncolytic 
HSV-1 derived from G207, with an additional 
deletion of ICP47 and the promoter region of US11
Suicide gene 
therapy
Suicide genes can change a nontoxic 
prodrug into a toxic substance that triggers 
apoptosis of tumor cells.
Suicide gene/prodrug
• HSVtk/ganciclovirl
• CD/5-flucytosine
CD: cytosine deaminase, GM-CSF: granulocyte–macrophage colony-stimulating factor, HSV: herpes simples virus, 
IFN-γ: interleukin interferon-gamma, IL: interleukin, TGF-β:transforming growth factor-beta, tk: thymidine kinase.
Table 1. Characteristics of gene therapies.
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replicate in tumor cells. Viral particles are released and spread to surrounding tumor cells. 
Oncolytic viral vectors cannot replicate in normal cells. Herpes simplex virus (HSV)-1 is the 
most famous oncolytic virus that has lower immunogenicity and stronger tumoricidal effects 
than adenovirus [22, 70].
HSV1716 is γ34.5 gene deleted HSV-1, constructed from wild-type strain. The γ34.5 gene 
of HSV-1 encodes ICP34.5. ICP34.5 gene counteracts the double-stranded RNA-dependent 
protein kinase (PKR)-mediated block to virus replication in post-mitotic cells. HSV1716 effec-
tively kills tumor cells because tumor cells have weaker defenses mediated by PKR pathway. 
The safety and toxicity of HSV1716 in patients have been demonstrated in a phase I clini-
cal trial for recurrent malignant glioma. Moreover, major neurological manifestation was not 
noted [55]. However, HSV1716 has the risk of being converted to the wild-type strain HSV-1 
because HSV1716 has only single gene deletion [18, 52].
G207 is a doubly mutated HSV-1, which has deletion of both γ34.5 loci and insertional 
inactivation of UL39. Ribonucleotide reductase (RR) encoded by UL39 is crucial for virus 
replication by catalyzing ribonucleotide formation. The lack of viral RR expression in G207 
specifically targets tumor cells because tumor cells have high RR activity. In addition, G207 
did not have the risk of being converted to the wild-type strain HSV-1. G207 was safe when 
it was inoculated into patients with recurrent malignant glioma in phase I or Ib clinical trials. 
Treatment-related toxicity or serious adverse events and evidence of HSV-1 encephalitis were 
not shown [39, 40, 42].
G47 delta is a new type of oncolytic HSV-1. G47 delta has an additional deletion of the gene 
encoding ICP47. G47 delta has the ability to enhance major histocompatibility complex class I 
antigen and immune response. In addition, this deletion causes promoter shift for the unique 
short 11 gene, which blocks the effect of IFNs and increases viral replication in tumor cells. A 
phase I/IIa clinical trial using G47 delta, which enhances specificity, and safety was conducted 
for recurrent or progressive glioblastoma in 2009 [72]. A phase II clinical trial using G47 delta 
was initiated from 2015 in a physician-led clinical trial.
OncoVEXGM−CSF is a first-in-class oncolytic vaccine approved by the FDA in 2015. It helps 
stimulate host immune response. ICP34.5 and ICP47 were deleted from HSV-1, and the gene 
encoding GM-CSF was inserted. A phase I clinical trial using OncoVEXGM−CSF was conducted 
for patients with breast, head and neck, and gastrointestinal cancers and malignant melanoma 
who had unsuccessful prior therapy. In the clinical trial, the virus had a good safety profile 
[24]. A phase II clinical trial for patients with unresectable metastatic melanoma showed 26% 
response rate [60]. Moreover, a phase III clinical trial showed significant prolonged overall 
survival for unresectable metastatic melanoma [27, 54].
Reovirus (Reolysin), which is a naturally occurring nonpathogenic, double-stranded RNA 
virus, has oncolytic activity and was also approved by the FDA. It was evaluated in phase I–III 
clinical trials in squamous cell carcinoma of the lungs and non-small-cell lung, pancreatic, and 
ovarian cancers. Its favorable toxicity profile, deficiency of viral shedding, and therapeutic 
effect have been shown in those clinical trials. A phase III trial of Reolysin combined with 
paclitaxel and carboplatin for treatment of head and neck squamous cell carcinoma was com-
pleted in 2014 [43].
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The 55-kda protein from the E1B region of an adenovirus binds to and inactivates the p53 
gene. ONYX-015 is an adenovirus modified to selectively replicate and kill cells that harbor 
p53 mutations [20]. A phase I clinical trial was conducted for patients with recurrent malig-
nant glioma. ONYX-015 showed promising safety profile; however, there was no significant 
therapeutic benefit [10].
Oncolytic virus therapy has been centered on various types of cancers and is expected to be 
applied for brain tumors. However, diffuse infiltration capacity of oncolytic virus to cover a 
large area invaded by malignant glioma might be one of the issues to solve.
2.3. Suicide gene therapy
Suicide genes can change a nontoxic prodrug into a toxic substance that triggers apoptosis of 
tumor cells [8, 69]. Herpes simplex virus thymidine kinase (HSVtk) + ganciclovir and cytosine 
deaminase (CD) + 5-flucytosine is the most famous combination. This therapy has a bystander 
killing effect, which results in the killing of a larger portion of cells than is transduced with 
the suicide gene [57]. In the 1990s, some clinical trials were conducted using viral vectors 
and fibroblasts that produce retrovirus for gene transduction. However, this therapy did not 
prolong the overall survival of patients with glioblastoma. This was considered to be caused 
by the vector’s low efficiency of gene transduction [9]. Toca 511, a retroviral replicating vector 
that delivers yeast CD, showed good results under the Toca FC administration in experimen-
tal brain tumor models, leading to a clinical trial [51].
2.4. Some types of stem cells
2.4.1. ESC
ESCs are derived from inner cell mass that can differentiate to triploblastic tissues. It has 
high telomerase activity that can persistently divide [30, 59]. Because the generation of ESCs 
involves the destruction of the preimplantation stage embryo, their use was controversial. In 
addition, ESCs can possibly lead to teratoma formation after transplantation. ESCs are also 
affected by immune rejection accompanied with ethical concerns because a fertile ovum is 
used. The first clinical trial that used ESCs was conducted in patients with severe subacute 
spinal injury in 2009. In that study, oligodendrocyte progenitor cells derived from ESCs were 
transplanted. Other clinical trials using ESCs have been previously conducted for some dis-
eases such as age-related macular degeneration and Stargardt disease. However, it has not 
been applied for brain tumor [59, 80].
2.4.2. MSC
MSCs can be harvested from fetal Wharton’s jelly adult bone marrow, synovialis, fatty tis-
sue, placenta, heart and liver. MSCs can be established by patients themselves. MSCs are not 
affected by host immune rejection [75]. Therefore MSCs tend to be easily linked to clinical 
applications. For example, endocapillary cells, myocardium, skeleton muscle, liver cell, neu-
ron, glial cell, insulin-producing cell and epithelial cell can be differentiated from MSCs. MSCs 
have been previously used for clinical trials such as head injury and cerebral infarction [23, 30].
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2.4.3. iPSC
iPSCs can be established directly from adult cells. Four specific genes (Oct3/4, c-myc, Sox2, 
and Klf4) encoding transcription factors could convert adult cells into iPSCs. iPSCs hold great 
promise in the field of regenerative medicine. iPSCs can also overcome some problems such as 
ethical concerns and immune rejection. Recently, iPSCs can be established without c-myc and 
can prevent teratoma formation [46, 49]. An episomal vector is used for the transduction to pre-
vent chromosomal insertion that cannot be accomplished by viral and plasmid vectors [50, 77]. 
In addition, iPSCs can be cultured under the feeder-free condition, and laminin-511 supports 
the stable culture of iPSCs [19]. The efficiency to culture iPSCs has been rapidly improved.
The first clinical trial for macular degeneration using autologous-induced stem cell-derived 
retinal cells has been completed in Japan in 2015. The feasibility of using iPSCs has been 
shown [38]. A clinical trial for Parkinson’s disease is expected to use iPSCs in the near future 
[12, 13, 16, 26, 48].
All types of stem cells have two important effects. First is the trophic effect, that is, supplying 
various nutrients and tissue-protective cytokines, and the second is the repairing effect, that is, 
identifying the damaged area and differentiating to an organized tissue after homing [23, 30].
2.5. Gene therapy using stem cells as delivery vehicle
2.5.1. Cytokine-based therapy
IL-4-producing NSCs showed powerful antitumor effects compared with that of the virus-
mediated delivery of IL-4 [7]. In addition, NSCs and MSCs that produce IL-2, IL-7, IL-12, 
and IL-23 have been evaluated for brain tumor [15, 17, 47, 61, 78, 79]. TNF-related apop-
tosis-inducing ligand (TRAIL) triggers caspase-8-dependent apoptosis. The tumor-specific 
therapeutic effects of TRAIL-producing NSCs, MSCs, and ESCs-derived astrocytes have been 
shown in experimental gliomas [29, 58].
2.5.2. Oncolytic virus therapy
Some studies showed the advantages of stem cells (NSCs and MSCs) to deliver replicating HSV 
and adenovirus because stem cells suppress the host immune response of the virus. In addition, 
stem cell therapy has become a promising approach because it can deliver viruses at further 
distance within the invaded malignant glioma [3, 5, 21, 68]. Actually, MSCs with replicating 
adenovirus showed that MSCs can suppress the immune response against the virus, which 
makes it possible to prolong viral activity and survival [4]. Some similar researches using NSCs 
with conditionally replicating HSV and adenovirus in preclinical studies were conducted [21].
2.5.3. Suicide gene therapy
Some reports showed that suicide gene therapy with HSVtk or CD using NSCs as cellular deliv-
ery vehicle could significantly prolong survival in animal models of brain tumor [28, 34, 37]. 
MSCs with HSVtk or CD were also used for the treatment of malignant glioma. Both NSCs 
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and MSCs could migrate even to the contralateral tumor [35, 41]. Mouse iPSC-derived NSCs 
with HSVtk have been previously reported and showed equivalent results as described above. 
However, the study using human iPSC-derived NSCs has not been reported, yet [36]. One pilot 
trial using NSCs with CD has been recently completed, but results are not yet available.
3. Future directions
The treatment concept of gene therapy was appropriate for malignant glioma; however, viral 
vectors are not enough to cover the large invasion area. The migration ability of stem cells has 
been expected. Some types of stem cells can be established recently. However, a comparative 
analysis on which type of stem cell has the strongest migration ability and the tumoricidal 
effect is needed. In brain tumor, NSCs may be considered as the most effective cellular vehicle 
because of their affinity to the brain. iPSCs are attractive tools because NSCs could be effi-
ciently differentiated from iPSCs. Gene therapy using stem cells as cellular delivery vehicles 
is expected to be further developed in the future.
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